Diplomat Pharmacy (DPLO) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Diplomat Pharmacy (NYSE:DPLO) from a sell rating to a hold rating in a research report released on Tuesday morning.

According to Zacks, “Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. It aids in the dispensing, delivery, dosing and reimbursement of clinically intensive and specialty drugs. The company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat Pharmacy, Inc. is headquartered in Flint, Michigan. “

Separately, ValuEngine lowered Diplomat Pharmacy from a hold rating to a sell rating in a report on Tuesday. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of Hold and an average target price of $25.20.

Shares of DPLO stock traded down $0.34 during mid-day trading on Tuesday, reaching $15.71. The stock had a trading volume of 64,580 shares, compared to its average volume of 765,330. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.63 and a current ratio of 0.91. The firm has a market capitalization of $1.51 billion, a PE ratio of 18.75 and a beta of 0.95. Diplomat Pharmacy has a 1-year low of $13.31 and a 1-year high of $28.74.

Diplomat Pharmacy (NYSE:DPLO) last announced its quarterly earnings data on Tuesday, November 6th. The company reported $0.01 earnings per share for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.21). The firm had revenue of $1.37 billion during the quarter, compared to analyst estimates of $1.42 billion. Diplomat Pharmacy had a net margin of 0.04% and a return on equity of 5.33%. The firm’s revenue for the quarter was up 22.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.01 earnings per share. Sell-side analysts forecast that Diplomat Pharmacy will post 0.81 earnings per share for the current year.

In related news, Director Philip R. Hagerman sold 209,367 shares of the firm’s stock in a transaction dated Thursday, September 13th. The stock was sold at an average price of $19.07, for a total transaction of $3,992,628.69. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Philip R. Hagerman sold 57,500 shares of the firm’s stock in a transaction dated Tuesday, September 11th. The stock was sold at an average price of $19.21, for a total value of $1,104,575.00. The disclosure for this sale can be found here. 24.70% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of DPLO. FMR LLC grew its holdings in Diplomat Pharmacy by 154.4% during the second quarter. FMR LLC now owns 2,798,440 shares of the company’s stock worth $71,528,000 after acquiring an additional 1,698,341 shares during the period. Frontier Capital Management Co. LLC grew its holdings in Diplomat Pharmacy by 84.1% during the third quarter. Frontier Capital Management Co. LLC now owns 3,535,217 shares of the company’s stock worth $68,619,000 after acquiring an additional 1,614,645 shares during the period. Janus Henderson Group PLC grew its holdings in Diplomat Pharmacy by 30.7% during the second quarter. Janus Henderson Group PLC now owns 5,385,168 shares of the company’s stock worth $137,645,000 after acquiring an additional 1,265,271 shares during the period. Victory Capital Management Inc. grew its holdings in Diplomat Pharmacy by 17,568.5% during the second quarter. Victory Capital Management Inc. now owns 1,239,442 shares of the company’s stock worth $31,679,000 after acquiring an additional 1,232,427 shares during the period. Finally, Rice Hall James & Associates LLC acquired a new stake in Diplomat Pharmacy during the second quarter worth about $20,932,000. 82.05% of the stock is currently owned by hedge funds and other institutional investors.

Diplomat Pharmacy Company Profile

Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company stocks, dispenses, and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. It also provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training/consulting, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.

See Also: Buyback

Get a free copy of the Zacks research report on Diplomat Pharmacy (DPLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply